Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Arthritis Research & Therapy|June 17, 2020
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina, Toru Hirano, Yuichi Maeda, et al.
JCI Insight|December 6, 2024
The pivotal role of the Hes1/Piezo1 pathway in the pathophysiology of glucocorticoid-induced osteoporosisNagahiro Ochiai, Yuki Etani, Takaaki Noguchi, et al.
Arthritis Research & Therapy|May 8, 2019
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Rheumatology International|October 18, 2019
The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort studyKoichi Murata, Motomu Hashimoto, Wataru Yamamoto, et al.
Arthritis Research & Therapy|April 12, 2019
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Plos One|May 9, 2019
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
BMC Rheumatology|May 14, 2026
Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trialShinsuke Yamada, Akira Onishi, Takumi Imai, et al.
Plos One|March 16, 2018
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort studyKosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, et al.
Modern Rheumatology|December 15, 2021
The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort studyKoichi Murata, Ryuji Uozumi, Motomu Hashimoto, et al.
Rheumatology (Oxford, England)|October 24, 2025
Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort studyYuri Hiramatsu, Takuya Kotani, Eri Nakamura, et al.
Pageof 16